BTX Stock In Action: Brooklyn ImmunoTherapeutics Moves up Again

Since March, the Brooklyn ImmunoTherapeutics Inc (NYSEAMERICAN:BTX) stock has been one of the biggest gainers, having clocked gains of 680%. This morning the stock is in focus yet again and has already jumped by 18% and made a new high of $31.50.

There has been no recent news about the company but earlier on in April Brooklyn ImmunoTherapeutics announced that it managed to license important technology from Novellus and Factor Bioscience. The technologies that have been acquired by the company are Cell Therapies and mRNA Gene Editing.

However, that is not all. Brooklyn ImmunoTherapeutics also extended the period within which it could exercise its option to get licensing agreements for other products to belong to the two above-mentioned companies.

On April 16, the company also named Howard J. Federoff as its new President and Chief Executive Officer. Federoff is also going to be a member of the company’s board of directors. It might be a good idea for investors to track the Brooklyn ImmunoTherapeutics stock at this point.

Anthony Gonzales

Biotech, Tech, and Crypto reporter Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.

Want Hot Stocks?    Yes. I Love Them No thanks